MINNEAPOLIS, Minn., March 17, 2026
Vergent Bioscience has announced the initiation of its Phase 3 VISUALIZE 2 pivotal clinical trial evaluating abenacianine (VGT-309), an investigational intraoperative imaging agent designed to enhance tumor visualization during lung cancer surgery. The study marks a critical step in advancing molecular imaging technology that enables real-time identification of malignant tissue, addressing a major limitation in minimally invasive and robotic-assisted surgical procedures.
Phase 3 Trial to Validate Clinical Efficacy and Safety
The VISUALIZE 2 trial is a randomized, multi-center, open-label Phase 3 study designed to confirm the safety and efficacy of abenacianine in lung cancer surgery, with planned enrollment of 132 patients across 10 clinical sites in the United States and Australia. Patients will receive a single intravenous infusion of abenacianine 12 to 96 hours prior to surgery, allowing the agent to bind to tumor-associated proteins and enable detection during the procedure.
The primary endpoint focuses on Clinically Significant Events (CSEs), defined as the ability to identify tumors or additional malignant tissue not detectable using standard surgical techniques. This endpoint highlights the growing importance of enhanced intraoperative visualization tools in improving surgical precision and patient outcomes. The trial represents a major milestone aligned with Good Clinical Practice (GCP) standards, emphasizing robust clinical evaluation, patient safety, and regulatory compliance.
Innovative Imaging Technology Enhances Surgical Precision
Advertisement
Abenacianine is a tumor-activated intraoperative imaging agent that uses near-infrared (NIR) fluorescence to illuminate cancerous tissue in real time, providing surgeons with molecular-level insight beyond traditional white-light visualization. The agent targets cathepsins, a family of proteases overexpressed in many solid tumors, enabling selective binding and enhanced detection of malignant cells.
This technology is particularly valuable in minimally invasive and robotic-assisted surgeries, where surgeons lack the ability to physically palpate tissue, making tumor localization more challenging. By integrating with existing NIR imaging systems already used in surgical settings, abenacianine offers a seamless addition to current workflows, improving decision-making without requiring major infrastructure changes.
Earlier Phase 2 and Phase 2b studies demonstrated that abenacianine improved intraoperative decision-making in up to 45% of surgeries, highlighting its potential to significantly enhance tumor detection and surgical outcomes. These findings underscore the role of advanced imaging technologies in transforming precision oncology and surgical practice.
Addressing Critical Needs in Lung Cancer Surgery
Lung cancer remains one of the leading causes of cancer-related mortality worldwide, and surgical resection is a cornerstone of treatment for many patients with solid tumors. However, the shift toward minimally invasive techniques, while beneficial for recovery and reduced trauma, introduces challenges in accurately identifying tumor boundaries.
Abenacianine aims to address this gap by providing real-time visualization of malignant tissue, enabling surgeons to achieve more complete tumor resections while preserving healthy tissue. This capability is expected to reduce recurrence rates, improve patient outcomes, and support more precise surgical interventions, aligning with the broader goals of personalized and precision medicine.
The successful development and potential approval of abenacianine could establish it as a critical operating room technology, particularly as healthcare systems increasingly adopt robotic and minimally invasive surgical approaches.
The initiation of the Phase 3 VISUALIZE 2 trial by Vergent Bioscience represents a significant advancement in clinical-stage oncology innovation, combining molecular imaging technology with surgical precision to improve cancer treatment outcomes. With strong early clinical data and a well-defined development pathway, abenacianine has the potential to transform intraoperative decision-making and redefine standards in lung cancer surgery. This development is highly relevant for the cGxP.wire audience, highlighting the importance of clinical trials, regulatory pathways, and technological innovation in advancing next-generation cancer therapies.
Source: Vergent bioscience press release
